Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Premature Birth | 4 | 2021 | 48 | 1.150 |
Why?
|
| Pre-Eclampsia | 3 | 2022 | 48 | 0.990 |
Why?
|
| Pregnancy Outcome | 4 | 2021 | 128 | 0.940 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 367 | 0.910 |
Why?
|
| Ovarian Neoplasms | 2 | 2019 | 563 | 0.760 |
Why?
|
| Cervical Length Measurement | 1 | 2021 | 2 | 0.740 |
Why?
|
| Nitrogen Oxides | 10 | 2005 | 40 | 0.740 |
Why?
|
| Pregnancy | 8 | 2022 | 1130 | 0.720 |
Why?
|
| Delivery, Obstetric | 1 | 2020 | 38 | 0.690 |
Why?
|
| Retrospective Studies | 9 | 2022 | 2444 | 0.690 |
Why?
|
| Gynecology | 1 | 2020 | 55 | 0.680 |
Why?
|
| Obstetrics | 1 | 2020 | 46 | 0.680 |
Why?
|
| Labor, Obstetric | 1 | 2019 | 11 | 0.670 |
Why?
|
| Labor, Induced | 1 | 2019 | 19 | 0.660 |
Why?
|
| Sesquiterpenes | 12 | 2007 | 22 | 0.640 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2018 | 15 | 0.630 |
Why?
|
| Trisomy 18 Syndrome | 1 | 2018 | 2 | 0.620 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2019 | 49 | 0.610 |
Why?
|
| Neuroprotective Agents | 9 | 2007 | 51 | 0.610 |
Why?
|
| Curriculum | 1 | 2020 | 262 | 0.610 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2018 | 36 | 0.600 |
Why?
|
| Peritoneal Neoplasms | 1 | 2019 | 76 | 0.600 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2018 | 43 | 0.580 |
Why?
|
| Internship and Residency | 1 | 2020 | 224 | 0.560 |
Why?
|
| Antioxidants | 9 | 2007 | 222 | 0.550 |
Why?
|
| Hypertension | 1 | 2018 | 304 | 0.510 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 67 | 0.510 |
Why?
|
| Female | 10 | 2022 | 14462 | 0.400 |
Why?
|
| Infant, Newborn | 4 | 2022 | 848 | 0.340 |
Why?
|
| Adult | 6 | 2020 | 7389 | 0.310 |
Why?
|
| Humans | 12 | 2022 | 26856 | 0.300 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2018 | 7 | 0.290 |
Why?
|
| Paclitaxel | 2 | 2019 | 183 | 0.270 |
Why?
|
| Alabama | 2 | 2020 | 4 | 0.220 |
Why?
|
| Parity | 2 | 2022 | 48 | 0.210 |
Why?
|
| Treatment Outcome | 3 | 2019 | 2267 | 0.190 |
Why?
|
| Gestational Age | 2 | 2022 | 140 | 0.190 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2021 | 18 | 0.180 |
Why?
|
| Spin Trapping | 2 | 1999 | 13 | 0.180 |
Why?
|
| Cervix Uteri | 1 | 2021 | 63 | 0.180 |
Why?
|
| Surgical Instruments | 1 | 2020 | 15 | 0.180 |
Why?
|
| Reference Values | 1 | 2019 | 198 | 0.160 |
Why?
|
| Brain Ischemia | 3 | 2007 | 80 | 0.160 |
Why?
|
| Stillbirth | 1 | 2018 | 14 | 0.160 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2018 | 12 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 233 | 0.160 |
Why?
|
| Clinical Competence | 1 | 2020 | 204 | 0.160 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 225 | 0.150 |
Why?
|
| Cisplatin | 1 | 2019 | 172 | 0.150 |
Why?
|
| Genetic Testing | 1 | 2018 | 64 | 0.150 |
Why?
|
| Aged | 2 | 2019 | 5169 | 0.150 |
Why?
|
| Young Adult | 3 | 2020 | 2584 | 0.150 |
Why?
|
| Chronic Disease | 1 | 2018 | 264 | 0.150 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 218 | 0.150 |
Why?
|
| Reperfusion Injury | 2 | 2012 | 31 | 0.140 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 472 | 0.140 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 509 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 588 | 0.130 |
Why?
|
| Taxoids | 1 | 2016 | 36 | 0.130 |
Why?
|
| Middle Aged | 2 | 2019 | 6825 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 108 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 67 | 0.130 |
Why?
|
| Carboplatin | 1 | 2016 | 106 | 0.130 |
Why?
|
| Papillomaviridae | 1 | 2016 | 85 | 0.130 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 457 | 0.120 |
Why?
|
| Brain | 3 | 2007 | 697 | 0.110 |
Why?
|
| Autocrine Communication | 1 | 2012 | 7 | 0.100 |
Why?
|
| Adenosine | 1 | 2012 | 33 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 44 | 0.100 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 1927 | 0.090 |
Why?
|
| Azulenes | 5 | 2005 | 5 | 0.090 |
Why?
|
| Kidney | 1 | 2012 | 274 | 0.090 |
Why?
|
| Rats | 7 | 2007 | 1536 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2007 | 537 | 0.090 |
Why?
|
| Oxidative Stress | 2 | 2007 | 619 | 0.080 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 1999 | 12 | 0.080 |
Why?
|
| Superoxide Dismutase | 2 | 1999 | 68 | 0.080 |
Why?
|
| Animals | 12 | 2012 | 9954 | 0.080 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2007 | 8 | 0.070 |
Why?
|
| Infarction, Middle Cerebral Artery | 2 | 2007 | 16 | 0.070 |
Why?
|
| Brain Damage, Chronic | 1 | 2007 | 4 | 0.070 |
Why?
|
| Resuscitation | 1 | 2007 | 59 | 0.070 |
Why?
|
| MPTP Poisoning | 2 | 2005 | 3 | 0.070 |
Why?
|
| Shock, Hemorrhagic | 1 | 2007 | 47 | 0.070 |
Why?
|
| Lung Diseases | 1 | 2007 | 41 | 0.070 |
Why?
|
| Myocardial Ischemia | 1 | 2007 | 73 | 0.070 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 151 | 0.070 |
Why?
|
| Male | 10 | 2022 | 12866 | 0.070 |
Why?
|
| Disease Models, Animal | 5 | 2007 | 1394 | 0.070 |
Why?
|
| Propionates | 1 | 2005 | 11 | 0.060 |
Why?
|
| Lung | 1 | 2007 | 346 | 0.060 |
Why?
|
| Kinetics | 2 | 2004 | 538 | 0.060 |
Why?
|
| Membrane Lipids | 1 | 2004 | 21 | 0.060 |
Why?
|
| Dopamine | 2 | 1999 | 21 | 0.050 |
Why?
|
| Peroxides | 1 | 2002 | 4 | 0.050 |
Why?
|
| Benzene Derivatives | 1 | 2002 | 7 | 0.050 |
Why?
|
| Nervous System Diseases | 1 | 2002 | 39 | 0.050 |
Why?
|
| Spin Labels | 2 | 1998 | 19 | 0.050 |
Why?
|
| Brain Injuries | 1 | 2002 | 49 | 0.050 |
Why?
|
| Controlled Before-After Studies | 1 | 2020 | 4 | 0.050 |
Why?
|
| Maternal Mortality | 1 | 2020 | 8 | 0.040 |
Why?
|
| Infant Mortality | 1 | 2020 | 15 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2020 | 89 | 0.040 |
Why?
|
| Free Radicals | 4 | 2004 | 39 | 0.040 |
Why?
|
| Retinal Ganglion Cells | 1 | 1999 | 26 | 0.040 |
Why?
|
| Parkinson Disease | 1 | 1999 | 38 | 0.040 |
Why?
|
| Logistic Models | 1 | 2020 | 397 | 0.040 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 1998 | 2 | 0.040 |
Why?
|
| Point Mutation | 1 | 1998 | 60 | 0.040 |
Why?
|
| Carotid Artery Diseases | 1 | 1998 | 37 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1998 | 44 | 0.040 |
Why?
|
| Ischemic Attack, Transient | 1 | 1998 | 25 | 0.040 |
Why?
|
| Infant | 1 | 2020 | 963 | 0.030 |
Why?
|
| Spinal Cord | 1 | 1998 | 202 | 0.030 |
Why?
|
| Stroke | 1 | 1999 | 233 | 0.030 |
Why?
|
| Mice | 4 | 2012 | 4402 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2012 | 1474 | 0.030 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2012 | 4 | 0.030 |
Why?
|
| 5'-Nucleotidase | 1 | 2012 | 13 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2012 | 37 | 0.030 |
Why?
|
| Models, Animal | 1 | 2012 | 128 | 0.020 |
Why?
|
| Time Factors | 2 | 2007 | 1564 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 2017 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2012 | 204 | 0.020 |
Why?
|
| Oxidation-Reduction | 2 | 2004 | 352 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 781 | 0.020 |
Why?
|
| Dinoprost | 1 | 2007 | 9 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2007 | 25 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 254 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2007 | 187 | 0.020 |
Why?
|
| Myocardium | 1 | 2007 | 171 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 244 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2007 | 388 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2012 | 1339 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2007 | 391 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2005 | 34 | 0.020 |
Why?
|
| Nitro Compounds | 1 | 2005 | 10 | 0.020 |
Why?
|
| Linoleic Acids | 1 | 2004 | 2 | 0.010 |
Why?
|
| Lipid Bilayers | 1 | 2004 | 15 | 0.010 |
Why?
|
| Solutions | 1 | 2004 | 31 | 0.010 |
Why?
|
| Micelles | 1 | 2004 | 19 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 2004 | 34 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 2004 | 45 | 0.010 |
Why?
|
| Nitriles | 1 | 2004 | 32 | 0.010 |
Why?
|
| Phosphatidylcholines | 1 | 2004 | 41 | 0.010 |
Why?
|
| Molecular Conformation | 1 | 2004 | 66 | 0.010 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2003 | 11 | 0.010 |
Why?
|
| Brain Edema | 1 | 2003 | 22 | 0.010 |
Why?
|
| Free Radical Scavengers | 1 | 2003 | 23 | 0.010 |
Why?
|
| Water | 1 | 2004 | 131 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2003 | 106 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2003 | 246 | 0.010 |
Why?
|
| 1-Methyl-4-phenylpyridinium | 1 | 1998 | 2 | 0.010 |
Why?
|
| N-Methylaspartate | 1 | 1998 | 4 | 0.010 |
Why?
|
| Superoxides | 1 | 1998 | 60 | 0.010 |
Why?
|
| Brain Chemistry | 1 | 1998 | 22 | 0.010 |
Why?
|
| Gerbillinae | 1 | 1998 | 1 | 0.010 |
Why?
|
| Electrochemistry | 1 | 1998 | 14 | 0.010 |
Why?
|
| Colorimetry | 1 | 1998 | 14 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 1998 | 50 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1998 | 93 | 0.010 |
Why?
|
| Cell Count | 1 | 1998 | 84 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1998 | 117 | 0.010 |
Why?
|
| Cell Death | 1 | 1998 | 110 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 1998 | 487 | 0.010 |
Why?
|
| Neurons | 1 | 1998 | 273 | 0.010 |
Why?
|
| Aging | 1 | 1998 | 954 | 0.010 |
Why?
|